When fatigue identified emotional ...

When asthenia revealed emotional lability, motivation, and sexual dysfunction, sleep disturbances, loss of appetite, memory, attention, hyperesthesia (increased sensitivity). Fatigue significantly impairs the quality of life for patients, leading to persistent and severe maladjustment. According to the etiology of fatigue is divided into organic and "functional." The most frequent causes of development of organic forms of asthenia - infectious, endocrine, neurological, cancer, hematological diseases, gastrointestinal dysfunction (including hepatitis), as well as the pathology of the immune system. "Functional" asthenic disorders suggest the existence of mental areas: mental illness manifests itself in different forms of depression, reactive and neurotic states, dysthymia, seasonal affective disorder. Asthenic syndrome always require treatment regardless of its etiology and stage of development. For the treatment of asthenic disorders, various drugs: nootropics, adaptogens of plant origin, and even some antidepressants antipsychotics. However, the stimulating properties of some of these drugs could increase the inherent fatigue irritability, sleep disorders, autonomic disorders, sedative effects of other aggravated lethargy and daytime sleepiness. Therefore, the creation of the drug with a balanced protivoastenicheskim action is an important medical and social problem. The most promising in this respect is the preparation Enerion submitted by pharmaceutical factory Egis (Hungary). Enerion is a synthetic compound derived from combining two molecules diizobutirata thiamine disulfide bridges. With a lipophilic, Enerion rapidly absorbed in the gastrointestinal tract and crosses the blood-brain barrier, accumulating in the structures of limbic-reticular complex and especially - in the reticular formation, hippocampus, dentate gyrus, Purkinje cells. Enerion proholinoliticheskim has a pronounced effect, potentiates serotoninergicheskuyu activity and promotes the re-synchronization of circadian rhythms. In the foreign literature contains data on the favorable results of Eneriona with fatigue in patients with coronary artery disease, with postinfectious asthenia, with irritable bowel syndrome in women in the postpartum period [8,9,11,12,13]. The aim of our study was to determine the efficacy and tolerability Enerion in treating patients with psycho-vegetative syndrome with pronounced asthenia. In the study group was selected 40 patients of both sexes (26 women and 14 men) aged 18 to 62 years (average age 37.2 years) with psycho-vegetative syndrome, in whose clinical picture was dominated by asthenic symptoms. Effectiveness of the Eneriona assessed by changes in subjective well-being of patients, changes in indicators of psychological tests and parameters of evoked potentials. Undesirable effect of the drug was recorded as using the normal forms and through a targeted survey.